FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials
The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products.
Here’s How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today
Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 19.59% on an annualized basis.
Intellia’s CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer
Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has
NaIntellia Therapeutics Granted FDA Designated Orphan Status For ‘ Autologous ex-vivo CRISPR/Cas9 engineered Wilms¿ tumor 1-specific T-cell receptor T cells’ For Treatment Of Acute Myeloid Leukemia
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=865021
63 Biggest Movers From Yesterday
Gainers
Indonesia Energy Corporation Limited (NASDAQ: INDO) shares climbed 39.3% to close at $20.20 on Thursday after jumping around 35% on Wednesday.
36 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday.
Chardan Capital Maintains Buy on Intellia Therapeutics, Lowers Price Target to $172
Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $177 to $172.